Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 204,918 | 192,574 | 161,709 | 141,148 | 120,856 |
| Cost of Goods | 33,510 | 38,142 | 28,093 | 18,938 | 15,541 |
| Gross Profit | 171,408 | 154,432 | 133,616 | 122,210 | 105,315 |
| Operating Expenses | 137,123 | 104,080 | 104,344 | 88,305 | 97,234 |
| Operating Income | 34,795 | 50,494 | 29,365 | 34,843 | 8,622 |
| Interest Expense | 7,666 | 6,533 | 6,721 | 6,716 | 6,757 |
| Other Income | -6,766 | 1,132 | 3,265 | 2,793 | 3,603 |
| Pre-tax Income | 20,363 | 45,093 | 25,909 | 30,920 | 5,468 |
| Income Tax | 586 | 22,056 | -364,986 | 2,733 | 408 |
| Net Income Continuous | 19,777 | 23,037 | 390,895 | 28,187 | 5,060 |
| Net Income | $19,777 | $23,037 | $390,895 | $28,187 | $5,060 |
| EPS Basic Total Ops | 0.14 | 0.19 | 2.69 | 0.19 | 0.03 |
| EPS Basic Continuous Ops | 0.14 | 0.18 | 2.69 | 0.19 | 0.03 |
| EPS Diluted Total Ops | 0.12 | 0.14 | 2.43 | 0.17 | 0.03 |
| EPS Diluted Continuous Ops | 0.12 | 0.14 | 2.43 | 0.17 | 0.03 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.14 | 2.43 | 0.17 | 0.03 |
| EBITDA(a) | $34,793 | $50,482 | $28,945 | $33,923 | $7,646 |